Evolution, Hypothalamic Dopamine Neurochemistry, and Developing New Therapies for Insulin Resistance Syndrome and Type 2 Diabetes
Evolution, Hypothalamic Dopamine Neurochemistry, and Developing New Therapies for Insulin Resistance Syndrome and Type 2 Diabetes
Program Description:
While genetic background and diet interact to potentiate the insulin resistance
syndrome, it is the neuroendocrine axis that regulates gene expression
and the impact of diet to control overall metabolism. Marked annual cycles between the obese, insulin resistant and lean, insulin sensitive states are well preserved across evolutionary time among vertebrate species in the wild and these seasonal shifts occur without any change in genome and cannot be explained fully by changes in caloric intake. A key element in this endogenous metabolic shift control-system is hypothalamic dopamine. Endogenous increases in hypothalamic dopamine activity at particular times of day function to initiate a hypothalamic neurophysiology operative
in the reversal of the insulin resistance syndrome. By mimicking the neuroendocrine dopaminergic activation driving the seasonal shift to the lean, insulin sensitive state it is possible to produce such shifts in metabolism
among a wide variety of genetic and dietary induced animal models of insulin resistance as well. Such findings have spawned clinical investigations
of bromocriptine, a dopamine D2 receptor agonist, for the treatment of metabolic disease, including type 2 diabetes. This symposium will review published data on a) preclinical studies of hypothalamic dopaminergic
activities operative in the reversal of the insulin resistance syndrome and related metabolic disease and b) clinical studies demonstrating the association of dopamine D2 receptor genotype and function with metabolic status and the potential utility of hypothalamic dopamine neuromodulation in the treatment of insulin resistance syndrome and type 2 diabetes.
5:30 to 5:40 AM: Introduction: Metabolic Syndrome and the Neuroendocrine System
Anthony H. Cincotta, PhD, Chief Science Officer, VeroScience LLC.
5:40 to 6:20 AM: Hypothalamic Dopamine and the Manifestation of Insulin Resistance Syndrome
Anthony H. Cincotta, PhD, Chief Science Officer, VeroScience LLC.
6:20 to 6:45 AM: Bromocriptine (Dopamine D2 receptor agonist) Influence on Hepatic Steatosis
Lisa Davis, PhD, PA-C, Johns Hopkins Bloomberg School of Public Health.
6:45 to 7:10 AM: Polymorphisms of the Dopamine D2 Receptor Gene and Obesity
G. Neil Thomas, PhD, University of Hong Kong, School of Public Health.
Program Description:
While genetic background and diet interact to potentiate the insulin resistance
syndrome, it is the neuroendocrine axis that regulates gene expression
and the impact of diet to control overall metabolism. Marked annual cycles between the obese, insulin resistant and lean, insulin sensitive states are well preserved across evolutionary time among vertebrate species in the wild and these seasonal shifts occur without any change in genome and cannot be explained fully by changes in caloric intake. A key element in this endogenous metabolic shift control-system is hypothalamic dopamine. Endogenous increases in hypothalamic dopamine activity at particular times of day function to initiate a hypothalamic neurophysiology operative
in the reversal of the insulin resistance syndrome. By mimicking the neuroendocrine dopaminergic activation driving the seasonal shift to the lean, insulin sensitive state it is possible to produce such shifts in metabolism
among a wide variety of genetic and dietary induced animal models of insulin resistance as well. Such findings have spawned clinical investigations
of bromocriptine, a dopamine D2 receptor agonist, for the treatment of metabolic disease, including type 2 diabetes. This symposium will review published data on a) preclinical studies of hypothalamic dopaminergic
activities operative in the reversal of the insulin resistance syndrome and related metabolic disease and b) clinical studies demonstrating the association of dopamine D2 receptor genotype and function with metabolic status and the potential utility of hypothalamic dopamine neuromodulation in the treatment of insulin resistance syndrome and type 2 diabetes.
5:30 to 5:40 AM: Introduction: Metabolic Syndrome and the Neuroendocrine System
Anthony H. Cincotta, PhD, Chief Science Officer, VeroScience LLC.
5:40 to 6:20 AM: Hypothalamic Dopamine and the Manifestation of Insulin Resistance Syndrome
Anthony H. Cincotta, PhD, Chief Science Officer, VeroScience LLC.
6:20 to 6:45 AM: Bromocriptine (Dopamine D2 receptor agonist) Influence on Hepatic Steatosis
Lisa Davis, PhD, PA-C, Johns Hopkins Bloomberg School of Public Health.
6:45 to 7:10 AM: Polymorphisms of the Dopamine D2 Receptor Gene and Obesity
G. Neil Thomas, PhD, University of Hong Kong, School of Public Health.
Comments